Adeptus Biotechnologies Corp. (ADPT) PT Raised to $27 at Morgan Stanley
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/21/2026
- Nasdaq leads gains as SpaceX, Super Micro results improve AI appetite
- SpaceX, Tesla shares rise after Musk says committees exploring possible merger
- Brent falls as Iran's president discusses mediation with Pakistani army chief
- Nvidia’s Huang highlights AI benefits in Berlin speech amid wider European tour
- AI bubble about to burst? Not yet, Yardeni says
Tweet
Share
E-mailGet Alerts ADPT Hot Sheet
Price: $25.33 +3.73%
Rating Summary:
13 Buy, 3 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 11 | Down: 17 | New: 13
Rating Summary:
13 Buy, 3 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 11 | Down: 17 | New: 13
Join SI Premium – FREE
Morgan Stanley analyst Kallum Titchmarsh raised the price target on Adeptus Biotechnologies Corp. (NASDAQ: ADPT) to $27.00 (from $22.00) while maintaining a Equalweight rating.
You May Also Be Interested In
- Adidas AG (ADS:GR) (ADDYY) PT Raised to EUR210 at StoneX on 'Robust' Pre-Announced Q3 Results
- 3M (MMM) PT Raised to $197 at Bernstein SocGen Group
- Barclays cuts Cirrus Logic price target to $95 from $130, cuts to Underweight
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
